Travere Therapeutics has achieved a significant milestone in the treatment of rare kidney diseases with the U.S. Food and Drug…
Read More
FDA Proposes Permanent Authorization of Rare Pediatric Disease Priority Review Voucher Program to Foster Regulatory Stability
The United States Food and Drug Administration (FDA) is making a significant move to permanently authorize the rare pediatric disease…
Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult Populations
Bristol Myers Squibb’s (BMS) groundbreaking immunotherapy, Opdivo (nivolumab), has achieved a significant milestone with dual approvals from the U.S. Food…
Read More
